"We have launched Novoeight in India for use in the treatment and prevention of bleeding in people with haemophilia A (congenital factor VIII deficiency) across all age groups. It can also be used to prevent excessive bleeding in people with haemophilia A undergoing surgery," a company statement issued here said.
"Turoctocog alfa represents a new treatment alternative for people with haemophilia A and is one of the first important outcomes of the haemophilia research strategy we embarked upon about a decade ago. The approval of 'Novoeight' marks an important step in offering a new alternative for people with haemophilia A," Novo Nordisk Corporate Vice President Business Area Gulf, India and Egypt, Mads Bo Larsen said.